Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher

The Bionomics Ltd (ASX: BNO) share price is in positive territory after announcing a non-renounceable entitlement offer. Here's the details.

| More on:
Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Bionomics Ltd (ASX: BNO) share price is in positive territory today after announcing a non-renounceable entitlement offer. During mid-afternoon trade, the clinical-stage biopharmaceutical company's shares are up 3.5% to 30 cents.

This takes the Bionomics share price to more than a 950% gain when compared to this time last year. Surprisingly, in March 2020, the company's shares were swapping hands for as little as 2.8 cents.

Details of the offer

In its announcement, Bionomics updated shareholders advising of a pro rata non- renounceable entitlement offer on a 1:6 basis. This follows the company's recent subscribed underwritten placement to North American and European institutional and sophisticated investors.

The offer price will be issued at the same rate to the previous placement, at 14.5 cents apiece. Notably, this represents a 50% discount on the current Bionomics share price of 29.5 cents. Moreover, the new shares will rank equally with existing ordinary shares.

The record date for the entitlement offer is on Thursday 11 March, 6:00pm Australian Central Daylight Time (ACDT). Unless extended, the placement will close 30 March, 5:00pm ACDT. The new shares will be allotted on 8 April 2021.

The expected take-up of the offer is estimated to bring in around $20 million in capital for the company. This will be used to partly fund a Phase 2b Post-Traumatic Stress Disorder trial for mid-2021. Additionally, the remaining monies will be spent towards general working capital purposes.

Quick take on Bionomics

Founded in 1996, Bionomics is a biopharmaceutical company that develops drug candidates to treat central nervous system disorders. This includes anxiety, depression, and Alzheimer's disease.

The company has offices in Australia, the United States, and France.

About the Bionomics share price

Over the last 12 months, the Bionomics share price has been one of the best performers on the ASX market. Positive investor sentiment in the company picked up towards September, and particularly shot higher in February.

Based on current valuations, Bionomics has a market capitalisation of close to $250 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

Why Harvey Norman, Macquarie Technology, Ramsay Health Care, and Star are rising

These ASX shares are having a strong day. But why?

Read more »

A young woman dressed in street clothes leaps happily in the air with the focus on her bright red boots that are front and centre for the camera.
Opinions

I'm listening to Warren Buffett and loading up on cheap ASX shares in March

I love the look of these stocks at these prices.

Read more »

A young woman sits on her bed holding a cup of coffee inside her recreational vehicle hired through the Camplify website
Cheap Shares

2 cheap ASX shares to add to your portfolio before they get expensive

I reckon this duo could see their stock prices rocket after they brush off temporary setbacks.

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Thursday

Will investors be leaping for joy on 29 February?

Read more »

A young man goes over his finances and investment portfolio at home.
Growth Shares

1 ASX growth stock down 30% to buy right now

The market has reacted badly to this ASX 200 company's half-year result. This could be your chance to get in.

Read more »

A female miner wearing a high vis vest and hard hard smiles and holds a clipboard while inspecting a mine site with a colleague.
Share Market News

Here's the Rio Tinto dividend forecast through to 2026

Here's what analysts are forecasting for the miner's dividend.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Dividend Investing

How I'd invest $250 a month in ASX dividend shares to target a $24,000 annual second income

Passive income is within the reach of ordinary Aussies, just like you. Yes, I said you!

Read more »

A man looking at his laptop and thinking.
Share Gainers

Should I buy Nvidia stock as an Australian investor?

Many Aussies are thinking of jumping on the bandwagon, but they need to think about these issues first.

Read more »